| |
Original Artikel |
Journal |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
Vaccine Insights |
2024―Mai―02 |
Maintaining ‘warm base’ capacity for pandemic preparedness |
Kilian Mullett |
| 2 |
[GO] |
Vaccine Insights |
2024―Mrz―14 |
Exploring hybrid mRNA vaccine technology for lasting immunity to COVID-19 |
Magnus Hoffmann |
| 3 |
[GO] |
Vaccine Insights |
2024―Mrz―14 |
Avian influenza and the risk of pandemic |
Mathilde Richard |
| 4 |
[GO] |
Vaccine Insights |
2023―Sep―13 |
Testing in times of COVID-19: legacy & unfinished agenda |
Carolina Batista, Yanis Ben Amor, Onder Ergonul, Peter Figueroa, Sarah C. Gilbert, Mayda Gursel, Emma Hannay, Mazen Hassanain, Peter Hotez, Gagandeep Kang, Jerome Kim, Bhavna Lall, Heidi Larson, Sarah-Jane Loveday, Denise Naniche, Timothy Sheahan, Shmuel Shoham, Nathalie Strub-Wourgaft, Samba Sow, Annelies Wilder-Smith, Prashant Yadav, Joe Fitchett, Amadou Sall, Maria Elena Bottazzi |
| 5 |
[GO] |
Vaccine Insights |
2023―Sep―13 |
Veterinary coronavirus vaccines: successes, challenges & lessons learned for SARS-CoV-2 control |
Anna Hassebroek, Xiang-Jin Meng |
| 6 |
[GO] |
Vaccine Insights |
2023―Sep―13 |
Unpacking the vaccine clinical trial ecosystem: implementing adaptive design, leveraging pandemic experience, & supporting resource-limited settings |
Sushant Sahastrabuddhe |
| 7 |
[GO] |
Vaccine Insights |
2023―Sep―07 |
Developing optimal pediatric COVID-19 vaccines for children younger than 12 years during an evolving pandemic |
Flor M Muñoz, Charu Sabharwal, Alejandra Gurtman, Emmanuel B Walter, Grant C Paulsen, Eric AF Simões, Caitlin Hansen, Luke Cunliffe, Stephen Lockhart, Hua Ma, Xia Xu, Kenneth Koury, Kena A Swanson, Nicholas Kitchin, William C Gruber, Annaliesa S Anderson |
| 8 |
[GO] |
Vaccine Insights |
2023―Sep―07 |
Lessons from COVID-19: how can vaccine clinical trials adapt to emerging threats? |
Daniel Hoft |
| 9 |
[GO] |
Vaccine Insights |
2023―Aug―08 |
Development of recombinant vesicular stomatitis virus vaccine platform for rapid response to Ebola and COVID-19 outbreaks |
Christopher Ton, Michael A Winters, Raymond Ducoat, Douglas D Richardson, Kristine Fuller, Melissa Hughes |
| 10 |
[GO] |
Vaccine Insights |
2023―Aug―08 |
Pandemic preparedness: the vaccine manufacturer’s perspective |
Jane True |
| 11 |
[GO] |
Vaccine Insights |
2023―Aug―08 |
Rapid manufacturing of vaccines for pandemic response & personalized cancer: parallels to leverage for common pathways to expedite clinical development? |
Antu K. Dey |
| 12 |
[GO] |
Vaccine Insights |
2023―Aug―08 |
OPENCORONA: lessons learned from a pandemic vaccine consortium |
Matti Sällberg, Eva-Karin Gidlund |
| 13 |
[GO] |
Vaccine Insights |
2023―Aug―02 |
Developing mRNA influenza vaccines in the wake of COVID-19 |
Raffael Nachbagauer |
| 14 |
[GO] |
Vaccine Insights |
2023―Aug―01 |
Vaccine supply chains: priority areas of action emerging from the COVID-19 pandemic |
Prashant Yadav, Carolina Batista, Ravi Anupindi, Sarah C. Gilbert, Bhavna Lall, Shmuel Shoham, Mayda Gursel, Yanis Ben Amor, Jerome Kim, Heidi Larson, Peter Figueroa, Nathalie Strub-Wourgaft, Samba Sow, Mazen Hassanain, Maria Elena Bottazzi, Peter Hotez |
| 15 |
[GO] |
Vaccine Insights |
2023―Jan―31 |
Why vaccinate children against COVID-19? |
David C Kaslow, Carolina Batista, Maria Elena Bottazzi, Onder Ergonul, J Peter Figueroa, Mayda Gursel, Mazen Hassanain, Peter Hotez, Gagandeep Kang, Bhavna Lall, Heidi Larson, Denise Naniche, Timothy Sheahan, Samba O Sow, Nathalie Strub-Wourgaft, Prashant Yadav, Annelies Wilder-Smith |
| 16 |
[GO] |
Vaccine Insights |
2023―Jan―31 |
Sourcing quality raw & starting materials at a reasonable cost during the pandemic |
Caryn Fenner |
| 17 |
[GO] |
Vaccine Insights |
2023―Jan―31 |
Discovery to delivery in 100 days: RNA therapeutics & their role in future pandemic preparedness |
Tracy Humphries |
| 18 |
[GO] |
Vaccine Insights |
2022―Aug―17 |
EATRIS: providing the right tools, at the right time, for vaccine development in a pandemic |
David Morrow, Lucia Gabriele, Antonio Andreu, Florence Bietrix, Anton Ussi, Jan Langermans |
| 19 |
[GO] |
Vaccine Insights |
2022―Jul―11 |
Vaccine development in the COVID-19 era: regulatory challenges & innovation |
Peter Marks, Marco Cavaleri, Carla Vinals, Adam Hacker |
| 20 |
[GO] |
Vaccine Insights |
2022―Jul―11 |
COVID-19 vaccine supply chain management: a LMIC perspective |
Darin Zehrung |
| 21 |
[GO] |
Vaccine Insights |
2022―Jul―11 |
COVID-19 vaccine supply chain management: a US perspective |
Michael Angelastro, Robert A Johnson |
| 22 |
[GO] |
Vaccine Insights |
2022―Jul―11 |
COVID-19: how is the pandemic changing the vaccines space? |
Nicholas Jackson |
| 23 |
[GO] |
Vaccine Insights |
2022―Jul―11 |
Guiding America through a pandemic |
Anthony S Fauci |
| 24 |
[GO] |
Vaccine Insights |
2022―Jul―11 |
Developing broadly protective strategies to protect against future pandemic threats |
Ralph Baric |
| 25 |
[GO] |
Cell and Gene Therapy Insights |
2022―Apr―06 |
Pandemic-related supply chain disruptions in cell therapy require rapid qualification for single-sourced materials |
John Duguid, Paul Friedman |
| 26 |
[GO] |
Cell and Gene Therapy Insights |
2022―Jan―28 |
Pandemic-related trends and challenges in adult donor stem cell and cord blood collection, banking, and processing |
Heidi Elmoazzen |
| 27 |
[GO] |
Cell and Gene Therapy Insights |
2022―Jan―17 |
COVID-19 vaccine approvals: key lessons for mRNA therapeutics |
Venkata Indurthi, PhD, Joseph Barberio, Scott Zobbi, Dr. Christoph Kröner |
| 28 |
[GO] |
Cell and Gene Therapy Insights |
2021―Okt―12 |
Leveraging lessons from the COVID-19 pandemic to accelerate the development and production of viral-based gene therapies |
Yasser Kehail |
| 29 |
[GO] |
Cell and Gene Therapy Insights |
2021―Aug―20 |
COVID-19 mRNA vaccine approvals: key lessons for cell & gene therapy and mRNA therapeutic development |
Joseph Barberio, Christoph Kröner, Venkata Indurthi, Scott Zobbi |
| 30 |
[GO] |
Cell and Gene Therapy Insights |
2021―Apr―12 |
Expect the unexpected: maintaining and optimizing a cell collection network during COVID-19 |
Amy Hines |
| 31 |
[GO] |
Cell and Gene Therapy Insights |
2021―Mrz―24 |
Considerations for performing virtual quality audits on manufacturers of gene therapy viral vectors: an auditor’s perspective during the COVID-19 public health emergency |
Gary C du Moulin, PhD, MPH, RAC |
| 32 |
[GO] |
Cell and Gene Therapy Insights |
2021―Mrz―23 |
The importance of a strong collection cell collection network during the COVID-19 pandemic |
Chris McClain, MBA |
| 33 |
[GO] |
Cell and Gene Therapy Insights |
2021―Jan―20 |
Navigating cell therapy supply chain complexities during the COVID-19 pandemic |
Erin Rasch |
| 34 |
[GO] |
Cell and Gene Therapy Insights |
2020―Nov―10 |
Managing donor collections during the COVID-19 pandemic |
Joy Aho |
| 35 |
[GO] |
Cell and Gene Therapy Insights |
2020―Aug―12 |
Targeting lung damage in COVID-19 patients with CD34+ cell therapy |
Douglas Losordo |
| 36 |
[GO] |
Cell and Gene Therapy Insights |
2020―Aug―12 |
Clinical trials in the era of Covid-19: successes, failures & ongoing challenges |
Sven Kili |
| 37 |
[GO] |
Cell and Gene Therapy Insights |
2020―Aug―12 |
Fighting a global pandemic with an army of robots |
Rennos Fragkoudis, Nikolaos Pantidos |
| 38 |
[GO] |
Cell and Gene Therapy Insights |
2020―Jul―16 |
Regulatory affairs in regen med: building trust, expediting development and navigating the impact of COVID-19 |
Manal Morsy |
| 39 |
[GO] |
Cell and Gene Therapy Insights |
2020―Jun―10 |
How will COVID-19 impact the cord blood banking sector? |
WOUTER VAN’T HOF |
| 40 |
[GO] |
Cell and Gene Therapy Insights |
2020―Mai―21 |
Cell therapy’s role in defeating Covid-19 |
Yaky Yanay |
